[O-29] Oral Session 29 Clinical trial and Regenerative medicine2

[O-29-5] Effect of satralizumab on relapse severity in neuromyelitis optica spectrum disorder (NMOSD)

^○Manabu Araki¹, Jacqueline Palace², Ingo Kleiter³, Anthony Traboulsee⁴, Takashi Yamamura⁵, Francesco Patti⁶, Daniela Stokmaier⁷, Gaelle Klingelschmitt⁷, Thomas Kuenzel⁷, H.-christian Von Büdingen⁷, Jeffrey L Bennett⁸ (1.Kawakita General Hospital, Tokyo, Japan, 2.John Radcliffe Hospital, Oxford, United Kingdom, 3.Ruhr University Bochum, Bochum, Germany, 4.University of British Columbia, Vancouver, Canada, 5.National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan, 6.University of Catania, Catania, Italy, 7.F. Hoffmann-La Roche Ltd, Basel, Switzerland, 8.University of Colorado School of Medicine, Aurora, CO, USA)